Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch

Set Alert for Stock Watch

Stock Watch: Biotech’s Commercial Laggards Drag On Sector

Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.

Stock Watch Commercial

Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom

Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.

Stock Watch M & A

Stock Watch: Big Pharma Earnings Season Gets Messy

A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.

Stock Watch Sales & Earnings

Stock Watch: The Pandemic Cannot Mask Roche’s Weaknesses

Declining COVID-19-related diagnostic and therapeutic sales are likely to expose long-standing weaknesses and amplify the effects of new pressures that were masked during the pandemic.

Stock Watch Sales & Earnings

Stock Watch: Second-Order Pandemic Effects In J&J’s First Quarter

The second-order pandemic effects on labor and logistics that have plagued other sectors appeared across J&J’s earnings announcement. With the biggest impact at its consumer business, why then has demand for J&J’s COVID-19 vaccine plummeted?

Stock Watch Companies

Stock Watch: Positive Trial Announcements Need A Pinch Of Salt

The announcement of a positive clinical trial and an intention to proceed to a regulatory submission are causes for a company’s investors to rejoice. Sometimes that can be premature.

Stock Watch Approvals

Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually

When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?

Stock Watch Companies

Stock Watch: The Meaning Of Biosimilar Success

With two recent divestments of biosimilar franchises and lackluster performances from smaller biosimilar biotechs, the sector needs some standard-bearing successes.

Stock Watch Biosimilars

Stock Watch: Brace For European Biotech Departures From NASDAQ

A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.

Stock Watch Financing

Stock Watch: The Competition Has It

Apart from assuming that its new drug will always be a blockbuster, the other common mistake made by biotech companies and investors is that there will invariably be a viable market for its drug. The competition will have other ideas.

Stock Watch Commercial

Stock Watch: Amarin And Esperion Cut Sales And Marketing Costs

Unlike big pharma, some small commercial companies cut sales and marketing costs in 2021. But with a little imagination, it could go further.

Stock Watch Sales & Earnings

Stock Watch: The Great Post-Pandemic Pharmaceutical Marketing Debate

Virtual marketing was the logical way to interact with healthcare professionals during the pandemic. It may stay after the pandemic but could be an additional expense.

Stock Watch Advertising, Marketing & Sales
UsernamePublicRestriction

Register